Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 08; 154(2):294-301.
View in:
PubMed
subject areas
Aged
Aged
Antineoplastic Agents, Phytogenic
Antineoplastic Agents, Phytogenic
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Bone and Bones
Bone and Bones
Carboplatin
Carboplatin
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Female
Female
Humans
Humans
Immunoglobulin Fc Fragments
Immunoglobulin Fc Fragments
Maximum Tolerated Dose
Maximum Tolerated Dose
Middle Aged
Middle Aged
Ovarian Neoplasms
Ovarian Neoplasms
Paclitaxel
Paclitaxel
Receptors, G-Protein-Coupled
Receptors, G-Protein-Coupled
Recombinant Fusion Proteins
Recombinant Fusion Proteins
Wnt Signaling Pathway
Wnt Signaling Pathway
authors with profiles
Kathleen Moore